Guo-Hua Qiu

Guo-Hua Qiu

Auto-generated profile, based on publicly available information

Guo-Hua Qiu

College of Life Sciences, Longyan University; Fujian Provincial Key Laboratory of Preventive Veterinary Medicine and Biotechnology; Engineering Research Center for the Prevention and Control of Animal-Origin Zoonosis; Key Laboratory for the Prevention and Control of Animal Infectious Diseases and Biotechnology, Fujian Province Universities, Longyan, PR China.

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2014 in Cytotechnology
Verified
Journal Article
Closed access
PDF file
GQGuo-Hua Qiu
Guo-Hua Qiu
XXXiaojin Xie
Xiaojin Xie
FXFang Xu
Fang Xu
XSXiaohao Shi
Xiaohao Shi
YWYue Wang
Yue Wang
LDLinhong Deng
Linhong Deng

1 September 2002 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
Qian TaoQian Tao
Qian Tao
HHHe Huang
He Huang
TGTheresa M. Geiman
Theresa M. Geiman
CLChai Yen Lim
Chai Yen Lim
LFLi Fu
Li Fu
KRKeith Robertson
Keith Robertson
ICF syndrome (immunodeficiency, centromere instability and facial anomalies) is a recessive human genetic disorder resulting from mutations in the DNA methyltransferase 3B (DNMT3B) gene. Patients with this disease exhibit numerous chromosomal abnormalities, including anomalous decondensation, pairing, separation and breakage, primarily involving the pericentromeric regions of chromosomes 1 and 16. Global levels of DNA methylation in ICF cells are only slightly reduced; however, certain repetitive sequences and genes on the inactive X chromosome of female ICF patients are significantly hypomethylated. In the present report, we analyze the molecular defect of de novo methylation in ICF cells in greater detail by making use of a model Epstein–Barr virus (EBV)-based system and three members of the unique cellular cancer–testis (C–T) gene family. Results with the EBV-based system indicate that de novo methylation of newly introduced viral sequences is defective in ICF syndrome. Limited de novo methylation capacity is retained in ICF cells, indicating that the mutations in DNMT3B are not complete loss-of-function mutations or that other DNMTs cooperate with DNMT3B. Analysis of three C–T genes (two on the X chromosome and one autosomal) revealed that loss of methylation from cellular gene sequences is heterogeneous, with both autosomal and X chromosome-based genes demonstrating sensitivity to mutations in DNMT3B. Aberrant hypomethylation at a number of loci examined correlated with altered gene expression levels. Lastly, no consistent changes in the protein levels of the DNA methyltransferases were noted when normal and ICF cell lines were compared.

3 May 2004 in Oncogene
Verified
Journal Article
Closed access
GQGuo-Hua Qiu
Guo-Hua Qiu
LTLuke Ks Tan
Luke Ks Tan
KLKwok Seng Loh
Kwok Seng Loh
CLChai Yen Lim
Chai Yen Lim
GSGopesh Srivastava
Gopesh Srivastava
Qian TaoQian Tao
Qian Tao

20 January 2009 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
JYJianming Ying
Jianming Ying
FPF F Poon
F F Poon
JYJun Yu
Jun Yu
HGH Geng
H Geng
AWA H Y Wong
A H Y Wong
Qian TaoQian Tao
Qian Tao
Promoter CpG methylation of tumour suppressor genes (TSGs) is an epigenetic biomarker for TSG identification and molecular diagnosis. We screened genome wide for novel methylated genes through methylation subtraction of a genetic demethylation model of colon cancer (double knockout of DNMT1 and DNMT3B in HCT116) and identified DLEC1 (Deleted in lung and oesophageal cancer 1), a major 3p22.3 TSG, as one of the methylated targets. We further found that DLEC1 was downregulated or silenced in most colorectal and gastric cell lines due to promoter methylation, whereas broadly expressed in normal tissues including colon and stomach, and unmethylated in expressing cell lines and immortalised normal colon epithelial cells. DLEC1 expression was reactivated through pharmacologic or genetic demethylation, indicating a DNMT1/DNMT3B-mediated methylation silencing. Aberrant methylation was further detected in primary colorectal (10 out of 34, 29%) and gastric tumours (30 out of 89, 34%), but seldom in paired normal colon (0 out of 17) and gastric (1 out of 20, 5%) samples. No correlation between DLEC1 methylation and clinical parameters of gastric cancers was found. Ectopic expression of DLEC1 in silenced HCT116 and MKN45 cells strongly inhibited their clonogenicity. Thus, DLEC1 is a functional tumour suppressor, being frequently silenced by epigenetic mechanism in gastrointestinal tumours.

12 February 2004 in Oncogene
Verified
Journal Article
Closed access
PDF file
PMPaul G Murray
Paul G Murray
GQGuo-Hua Qiu
Guo-Hua Qiu
LFLi Fu
Li Fu
EWElyse R Waites
Elyse R Waites
GSGopesh Srivastava
Gopesh Srivastava
Qian TaoQian Tao
Qian Tao

1 April 2007 in Journal of Hepatology
Verified
Journal Article
Closed access
GQGuo-Hua Qiu
Guo-Hua Qiu
HXHuangming Xie
Huangming Xie
Nick WheelhouseNick Wheelhouse
Nick Wheelhouse
DHDavid Harrison
David Harrison
GCGeorge G. Chen
George G. Chen
SHShing Chuan Hooi
Shing Chuan Hooi